In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes

Journal of Drug Targeting

Volumn 18, Issue 7, 2010, Pages 536-549

  Qin, Yao ^a,b   Fan, Wei ^a   Chen, Huali ^a   Yao, Nian ^a   Tang, Wenwei ^a   Tang, Jie ^a   Yuan, Wenmin ^a   Kuai, Rui ^a   Zhang, Zhirong ^a   Wu, Yong ^a   He, Qin ^a  

^a West China School of Pharmacy   (China)

^b Taiji Group   (China)

Author keywords

Biodistribution; Blood brain barrier; Brain targeting; Cytotoxicity; Glucose; Liposome; Transendothelial

Indexed keywords

COUMARIN; COUMARIN 6; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 4; GLUCOSE; GLUCOSE TRANSPORTER 1; LIPOSOME; UNCLASSIFIED DRUG; CHOLESTEROL; COUMARIN DERIVATIVE; GLUCOSE TRANSPORTER; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; BRAIN CAPILLARY; CAPILLARY ENDOTHELIUM; COCULTURE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CHOLESTEROL; COUMARINS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; LIPOSOMES; MICE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES; TISSUE DISTRIBUTION;

EID: 77954266282     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003587235     Document Type: Article

References (37)

1. Battaglia G, La Russa M, Bruno V, Arenare L, Ippolito R, Copani A, Bonina F, Nicoletti F. (2000). Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res, 860, 149-156.
2. Begley DJ, Brightman MW. (2003). Structural and functional aspects of the blood-brain barrier. Prog Drug Res, 61, 39-78.
3. Begley DJ. (2004). Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ter, 104, 29-45.
4. Bonina FP, Arenare L, Ippolito R, Boatto G, Battaglia G, Bruno V, de Caprariis P. (2000). Synthesis, pharmacokinetics and anticon-vulsant activity of 7-chlorokynurenic acid prodrugs. Int J Pharm, 202, 79-88.
5. Chen Q, Gong T, Liu J, Wang X, Fu H, Zhang Z. (2009). Synthesis in vitro and in vivo Characterization of Glycosyl Derivatives of Ibuprofen as Novel Prodrugs for Brain Drug Delivery. J Drug Target, 4, 318-328.
6. Chertok B, David AE, Mofat BA, Yang VC. (2009). Substantiating in vivo magnetic brain tumor targeting of cationic iron oxidenanocarriers via adsorptive surface masking. Biomaterials, 30, 6780-6787.
7. Choeiri C, Staines W, Messier C. (2002). Immunohistochemical localization and quantifcation of glucose transporters in the mouse brain. Neuroscience, 111, 19-34.
8. Dick AP, Harik SI, Klip A, Walker DM. (1984). Identifcation and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc Natl Acad Sci USA, 81, 7233-7237.
9. Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, Men Y, Guo J, Zhang Y, Li RJ, Zhou J, Lou JN, Wang JC, Zhang X, Zhang Q. (2008). Dual-targeting topotecan liposomes modifed with tamoxifen and wheat germ agglutinin signifcantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm, 6, 905-917
10. Dufes C, Gaillard F, Uchegbu I F, Schätzlein AG, Olivier JC, Muller JM. (2004). Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm, 285, 77-85.
11. Dwyer DS, Vannucci SJ, Simpson IA. (2002). Expression, regulation, and functional role of glucose transporters (GLUTs) in brain. Int Rev Neurobiol, 51, 159-188.
12. Fernández C, Nieto O, Rivas E, Montenegro G, Fontenla JA, Fernández-Mayoralas A. (2000). Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res, 327, 353-365.
13. Francesco B, Carmelo P, Maria GR, Daniela M, Giampiero B, Maria N, Antonio C, Giovanna LR, Paolo De C. (2003). Glycosyl Derivatives of Dopamine and L-dopa as Anti-Parkinson Prodrugs: Synthesis, Pharmacological Activity and In Vitro Stability Studies. J Drug Target,11, 25-36.
14. Halmos T, Santarromana M, Antonakis K, Scherman D. (1997). Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohydr Res, 299, 15-21.
15. Han HD, Lee A, Song CK, Hwang T, Seong H, Lee CO, Shin BC. (2006). In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Phar, 313, 181-188.
16. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release, 134, 55-61.
17. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. (2002). By-passing of P-glycoprotein using immunoliposomes. J Drug Target, 10, 73-79.
18. Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release, 127, 97-109.
19. Jeliazkova-Mecheva VV, Bobilya DJ. (2003). A porcine astrocyte/ endothelial cell co-culture model of the blood-brain barrier. Brain Res Brain Res Protocols, 12, 91-98.
20. LaManna JC, Harik SI. (1985). Regional comparisons of brain glucose infux. Brain Res, 326, 299-305.
21. Lu W, Tan YZ, Hu KL, Jiang XG. (2005). Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little tox-icity against blood-brain barrier. Int J Pharm, 295, 247-260.
22. McEwen BS, Reagan L P. (2004). Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol, 490, 13-24.
23. Nualart F, Godoy A, Reinicke K. (1999). Expression of the hexose transporters GLUT1 and GLUT2 during the early development of the human brain. Brain Res, 824, 97-104.
24. Pardridge WM. (2003). Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv, 3, 90-105.
25. Pardridge WM. (2005). Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int Con Series, 1277, 49-62.
26. Piferi F, Jouin M, Alessandri JM, Haedke U, Roux F, Perrière N, Denis I, Lavialle M, Guesnet P. (2007). n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukot Essent Fatty Acids, 77, 279-286.
27. Polt R, Porreca F, Szabò LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Harvath R, Yamamura HI, Hruby VJ. (1994). Glycopeptide enkepha-lin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci USA, 91, 7114-7118.
28. Qutub AA, Hunt CA. (2005). Glucose transport to the brain: a systems model. Brain Res Brain Res Rev, 49, 595-617.
29. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN, Manohar S, Liang HF, Kulkarni AR, Sung HW, Sairam M, Aminabhavi TM. (2005). Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release, 108, 193-214.
30. Schubert D. (2005). Glucose metabolism and Alzheimer's disease. Ageing Res Rev, 4, 240-257.
31. Shimada K, Kamps JA, Regts J, Ikeda K, Shiozawa T, Hirota S, Scherphof GL. (1997). Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s. Biochim Biophys Acta, 1326, 329-341.
32. Sifinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB. (1987). Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol, 132, 111-117.
33. Temsamani J, Scherrmann JM, Rees AR, Kaczorek M. (2000). Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm Sci Technol Today, 3, 155-162.
34. Xie Y, Ye L, Zhang X, Cui W, Lou J, Nagai T, Hou X. (2005). Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J Control Release, 105, 106-119.
35. Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q. (2009). Dual-targeting daunorubicin liposomes improve the therapeutic efcacy of brain glioma in animals. J Control Release, [Epub ahead of print].
36. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. (2007). Cholesterol as a Bilayer Anchor for PEGylation and Targeting Ligand in Folate-Receptor-Targeted Liposomes. J Pharm Sci, 96, 2424-2435.
37. Zhi RZ, Wei ZL, Nagai, T. (2001). Studies on hydrolysis kinetics and photolysis kinetics of N1-retinoyl-5-fuorouracil. STP Pharma Sci, 11, 243-246.